Metaplastic carcinoma of the breast Advocacy Hub | UniteRare

At a Glance

Live from database

💊

Regulatory Watchboard

3 events

May 2023PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

MedSIR — PHASE2

TrialACTIVE NOT RECRUITING

Jan 2023Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

The Methodist Hospital Research Institute — PHASE2

TrialRECRUITING

May 1997

Fareston: FDA approved

Treatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Copay cards

Copay Assistance2

Enhertu

Daiichi Sankyo and AstraZeneca

OpenContact for detailsApply ↗

ABRAXANE

Bristol Myers Squibb

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

2 FDA-approved

Fareston

(Toremifene)Orphan drug

Orion Corporation

12.1 Mechanism of Action Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, a...

Approved May 1997FDA label ↗

Abraxane

(paclitaxel protein-bound particles)Orphan drugstandard

Abraxis BioScience, LLC

Microtubule Inhibitor [EPC]

12.1 Mechanism of Action ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubule...

FDA label ↗

View full treatment details on disease page →